Matjaž Šinkovec
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matjaž Šinkovec has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Andrej Pernat
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Department of Cardiology, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia
4 shared publicationsBor Antolič
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Department of Cardiology, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia
3 shared publicationsLuka Klemen
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
3 shared publications- Bor Antolič
Department of Cardiology, University Medical Centre Ljubljana , Ljubljana
2 shared publications - Matevž Jan
Department of Cardiovascular Surgery, University Medical Centre Ljubljana , Ljubljana
2 shared publications Peter Rakovec
Department of Cardiology , University Medical Center , Zaloska 7, SI-1525 Ljubljana , Slovenia
2 shared publications
Latest Publications
- Open Access
- 28 February 2025
- Published by Slovenian Medical Association in Slovenian Medical Journal
- Vol. 94 (1-2) , 3-15
Early atrial ectopic beats and atrial conduction delay predict atrial fibrillation
Background: Atrial fibrillation/flutter (AF/AFl) is commonly diagnosed arrhythmia, associated with increased morbidity and mortality. Therefore, we have to improve our early AF/AFl diagnostics. Several studies indicated association between conduction delay, excessive atrial ectopic beats (AEBs) and AF/AFl onset. Association with some other AEB features is less clear. Objective: To validate the role of early AEBs from Holter-ECG in relation to documented AF/AFl events. Methods and Results: We enrolled 14 consecutive patients (6 female, median 60.5 years) with documented AF/AFl during or within 6 months after Holter-ECG (AF-group). Control group consisted of 10 clinically similar consecutive patients (5 female, median 64.5 years), without any evidence of AF/AFl, but with comparable burden of AEBs. Holter-ECGs were examined with 3-channel Holter system (Schiller, Darwin2 software). 24-hour data were analyzed for number and/or burden (%) of: a) AF/AFl, b) AEBs, c) early-AEBs (coupling interval cut-off <530 ms), d) AEB pairs, triplets, runs, and e) bigeminy. In addition, P-wave duration (cut-off <130 ms), PQ, QRS, and QTc were measured. AF-group had higher burden of early-AEBs (p<0.03) and longer P-waves (p<0.05) than controls. In both groups, non-conducted and aberrantly-conducted early-AEBs, AEBs in bigeminy, pairs, triplets and runs were found, as-well-as no difference for PQ, QRS, and QTc (p=NS). The majority of 243 AF/AFl events started during day-time and in 83% with early-AEBs. Before AF onset, outbursts of early-AEBs were encountered in 58% of patients. Conclusion: A higher burden of early AES in the Holter ECG and a longer P-wave duration predict the occurrence of AF/AU.
- 28 February 2025
- Published by Slovenian Medical Association in Slovenian Medical Journal
- Vol. 94 (1-2) , 3-15
Open AccessEarly atrial ectopic beats and atrial conduction delay predict atrial fibrillation
Background: Atrial fibrillation/flutter (AF/AFl) is commonly diagnosed arrhythmia, associated with increased morbidity and mortality. Therefore, we have to improve our early AF/AFl diagnostics. Several studies indicated association between conduction delay, excessive atrial ectopic beats (AEBs) and AF/AFl onset. Association with some other AEB features is less clear. Objective: To validate the role of early AEBs from Holter-ECG in relation to documented AF/AFl events. Methods and Results: We enrolled 14 consecutive patients (6 female, median 60.5 years) with documented AF/AFl during or within 6 months after Holter-ECG (AF-group). Control group consisted of 10 clinically similar consecutive patients (5 female, median 64.5 years), without any evidence of AF/AFl, but with comparable burden of AEBs. Holter-ECGs were examined with 3-channel Holter system (Schiller, Darwin2 software). 24-hour data were analyzed for number and/or burden (%) of: a) AF/AFl, b) AEBs, c) early-AEBs (coupling interval cut-off <530 ms), d) AEB pairs, triplets, runs, and e) bigeminy. In addition, P-wave duration (cut-off <130 ms), PQ, QRS, and QTc were measured. AF-group had higher burden of early-AEBs (p<0.03) and longer P-waves (p<0.05) than controls. In both groups, non-conducted and aberrantly-conducted early-AEBs, AEBs in bigeminy, pairs, triplets and runs were found, as-well-as no difference for PQ, QRS, and QTc (p=NS). The majority of 243 AF/AFl events started during day-time and in 83% with early-AEBs. Before AF onset, outbursts of early-AEBs were encountered in 58% of patients. Conclusion: A higher burden of early AES in the Holter ECG and a longer P-wave duration predict the occurrence of AF/AU.
- Open Access
- 24 April 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (5)
Impact of preventive substrate catheter ablation on implantable cardioverter-defibrillator interventions in patients with ischaemic cardiomyopathy and infarct-related coronary chronic total occlusion
Primary prevention patients with ischaemic cardiomyopathy and chronic total occlusion of an infarct-related coronary artery (CTO) are at a particularly high risk of implantable cardioverter-defibrillator (ICD) therapy occurrence. The trial was designed to evaluate the efficacy of preventive CTO-related substrate ablation strategy in ischaemic cardiomyopathy patients undergoing primary prevention ICD implantation. The PREVENTIVE VT study was a prospective, multicentre, randomized trial including ischaemic patients with ejection fraction ≤40%, no documented ventricular arrhythmias (VAs), and evidence of scar related to the coronary CTO. Patients were randomly assigned 1:1 to a preventive substrate ablation before ICD implantation or standard therapy with ICD implantation only. The primary outcome was a composite of appropriate ICD therapy or unplanned hospitalization for VAs. Secondary outcomes included the primary outcome’s components, the incidence of appropriate ICD therapies, cardiac hospitalization, electrical storm, and cardiovascular (CV) mortality. Sixty patients were included in the study. During the mean follow-up of 44.7 ± 20.7 months, the primary outcome occurred in 5 (16.7%) patients undergoing preventive substrate ablation and in 13 (43.3%) patients receiving only ICD [hazard ratio (HR): 0.33; 95% confidence interval (CI): 0.12–0.94; P = 0.037]. Patients in the preventive ablation group also had fewer appropriate ICD therapies (P = 0.039) and the electrical storms (Log-rank: P = 0.01). While preventive ablation also reduced cardiac hospitalizations (P = 0.006), it had no significant impact on CV mortality (P = 0.151). Preventive ablation of the coronary CTO-related substrate in patients undergoing primary ICD implantation is associated with the reduced risk of appropriate ICD therapy or unplanned hospitalization due to VAs. Preventive ablation of coronary total occlusion-related substrate at the time of primary prevention defibrillator implantation is associated with a reduced risk of appropriate defibrillator therapy or unplanned hospitalization due to ventricular arrhythmias.
- 24 April 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (5)
Open AccessImpact of preventive substrate catheter ablation on implantable cardioverter-defibrillator interventions in patients with ischaemic cardiomyopathy and infarct-related coronary chronic total occlusion
Primary prevention patients with ischaemic cardiomyopathy and chronic total occlusion of an infarct-related coronary artery (CTO) are at a particularly high risk of implantable cardioverter-defibrillator (ICD) therapy occurrence. The trial was designed to evaluate the efficacy of preventive CTO-related substrate ablation strategy in ischaemic cardiomyopathy patients undergoing primary prevention ICD implantation. The PREVENTIVE VT study was a prospective, multicentre, randomized trial including ischaemic patients with ejection fraction ≤40%, no documented ventricular arrhythmias (VAs), and evidence of scar related to the coronary CTO. Patients were randomly assigned 1:1 to a preventive substrate ablation before ICD implantation or standard therapy with ICD implantation only. The primary outcome was a composite of appropriate ICD therapy or unplanned hospitalization for VAs. Secondary outcomes included the primary outcome’s components, the incidence of appropriate ICD therapies, cardiac hospitalization, electrical storm, and cardiovascular (CV) mortality. Sixty patients were included in the study. During the mean follow-up of 44.7 ± 20.7 months, the primary outcome occurred in 5 (16.7%) patients undergoing preventive substrate ablation and in 13 (43.3%) patients receiving only ICD [hazard ratio (HR): 0.33; 95% confidence interval (CI): 0.12–0.94; P = 0.037]. Patients in the preventive ablation group also had fewer appropriate ICD therapies (P = 0.039) and the electrical storms (Log-rank: P = 0.01). While preventive ablation also reduced cardiac hospitalizations (P = 0.006), it had no significant impact on CV mortality (P = 0.151). Preventive ablation of the coronary CTO-related substrate in patients undergoing primary ICD implantation is associated with the reduced risk of appropriate ICD therapy or unplanned hospitalization due to VAs. Preventive ablation of coronary total occlusion-related substrate at the time of primary prevention defibrillator implantation is associated with a reduced risk of appropriate defibrillator therapy or unplanned hospitalization due to ventricular arrhythmias.
- Open Access
- 30 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7420
How Imaging Techniques Improve Ventricular Arrhythmia Ablation: A Multimodality-Based Approach
Although implantable cardioverter defibrillators offer the best protection against sudden cardiac death, catheter ablation for ventricular arrhythmias (VAs) can modify or prevent this event from occurring. In order to achieve a successful ablation, the correct identification of the underlying arrhythmogenic substrate is mandatory to tailor the pre-procedural planning of an ablative procedure as appropriately as possible. We propose that several of the imaging modalities currently used could be merged, including echocardiography (also intracardiac), cardiac magnetic resonance, cardiac computed tomography, nuclear techniques, and electroanatomic mapping. The aim of this state-of-the-art review is to present the value of each modality, that is, its benefits and limitations, in the assessment of arrhythmogenic substrate. Moreover, VAs can be also idiopathic, and in this paper we will underline the role of these techniques in facilitating the ablative procedure. Finally, a hands-on workflow for approaching such a VA and future perspectives will be presented.
- 30 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7420
Open AccessHow Imaging Techniques Improve Ventricular Arrhythmia Ablation: A Multimodality-Based Approach
Although implantable cardioverter defibrillators offer the best protection against sudden cardiac death, catheter ablation for ventricular arrhythmias (VAs) can modify or prevent this event from occurring. In order to achieve a successful ablation, the correct identification of the underlying arrhythmogenic substrate is mandatory to tailor the pre-procedural planning of an ablative procedure as appropriately as possible. We propose that several of the imaging modalities currently used could be merged, including echocardiography (also intracardiac), cardiac magnetic resonance, cardiac computed tomography, nuclear techniques, and electroanatomic mapping. The aim of this state-of-the-art review is to present the value of each modality, that is, its benefits and limitations, in the assessment of arrhythmogenic substrate. Moreover, VAs can be also idiopathic, and in this paper we will underline the role of these techniques in facilitating the ablative procedure. Finally, a hands-on workflow for approaching such a VA and future perspectives will be presented.
- Open Access
- 3 February 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 14, 154-159
Hemodynamic responses to low-level transcutaneous auricular nerve stimulation in young volunteers
- 3 February 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 14, 154-159
Open AccessHemodynamic responses to low-level transcutaneous auricular nerve stimulation in young volunteers
- 1 December 2021
- Published by Elsevier in Autonomic Neuroscience
- Vol. 236, 102851
Cardiovascular responses to low-level transcutaneous vagus nerve stimulation
- 1 December 2021
- Published by Elsevier in Autonomic Neuroscience
- Vol. 236, 102851
Cardiovascular responses to low-level transcutaneous vagus nerve stimulation
- Open Access
Design and Clinical Evaluation of a Non-Contact Heart Rate Variability Measuring Device
The object of the proposed paper is to design and analyze the performance of a non-contact heart rate variability (HRV) measuring device based on ultrasound transducers. The rationale behind non-contact HRV measurement is the goal of obtaining a means of long term monitoring of a patient’s heart performance. Due to its complexity as a non-contact measuring device, influential physical quantities, error source and other perturbations were thoroughly investigated. For medical purposes it is of utmost importance to define the target uncertainty of a measuring method from the side of physicians, while it is the role of scientists to realistically evaluate all uncertainty contributions. Within this paper we present a novelty method of non-contact HRV measurement based on ultrasound transducers operating at two frequencies simultaneously. We report laboratory results and clinical evaluations are given for healthy subjects as well as patients with known heart conditions. Furthermore, laboratory tests were conducted on subjects during a relaxation period, and after 1 min physical activity
Open AccessDesign and Clinical Evaluation of a Non-Contact Heart Rate Variability Measuring Device
The object of the proposed paper is to design and analyze the performance of a non-contact heart rate variability (HRV) measuring device based on ultrasound transducers. The rationale behind non-contact HRV measurement is the goal of obtaining a means of long term monitoring of a patient’s heart performance. Due to its complexity as a non-contact measuring device, influential physical quantities, error source and other perturbations were thoroughly investigated. For medical purposes it is of utmost importance to define the target uncertainty of a measuring method from the side of physicians, while it is the role of scientists to realistically evaluate all uncertainty contributions. Within this paper we present a novelty method of non-contact HRV measurement based on ultrasound transducers operating at two frequencies simultaneously. We report laboratory results and clinical evaluations are given for healthy subjects as well as patients with known heart conditions. Furthermore, laboratory tests were conducted on subjects during a relaxation period, and after 1 min physical activity
- Open Access
- 1 September 2017
- Published by Slovenian Medical Association in Slovenian Medical Journal
- Vol. 86 (7-8)
Catheter ablation of repetitive ventricular tachycardia in patients with ischemic heart disease – our experience
Ventricular tachycardia (VT) poses a significant risk for sudden death and heart failure exacerbation in patients with ischemic heart disease. Catheter-based radiofrequency ablation is the last treatment option for patients with frequent VT recurrences despite antiarrhythmic drugs. The aim was to present our retrospective catheter ablation data in this group of patients. The majority of 34 patients, who underwent percutaneous endocardial radiofrequency catheter ablation, were male, median age 67.5 years, who presented with electrical storm, had underlying cardiomyopathy after remote inferior wall myocardial infarction and preceding myocardial revascularization procedure, and had been implanted with cardioverter-defibrillator (ICD). Two ablation methods were used: linear ablation and/or scar homogenization. Acute ablation success (non-inducibility of any VT) was achieved in 59 % of procedures. VT could not be interrupted in 2 (6 %) patients. Pericardial tamponade that needed surgical intervention occurred in one procedure (2 %), and was related to inadvertent perforation of the right ventricular apex with a diagnostic catheter. Seven (20 %) patients died and additional 3 were lost from the median of 31 (6–151, rank) months of follow-up. No late VT recurrences were demonstrated in 20 (59 %) patients, and rare in 4 (12 %). Overall, the ablation procedure was successful in 71 % of patients. Catheter ablation gave very good long-term clinical result in about two-thirds of our patients with ischaemic cardiomyopathy and frequent VT recurrences. Catheter ablation, preferably with scar homogenization approach, should be considered early to reduce the number of VT episodes and ICD discharges.
- 1 September 2017
- Published by Slovenian Medical Association in Slovenian Medical Journal
- Vol. 86 (7-8)
Open AccessCatheter ablation of repetitive ventricular tachycardia in patients with ischemic heart disease – our experience
Ventricular tachycardia (VT) poses a significant risk for sudden death and heart failure exacerbation in patients with ischemic heart disease. Catheter-based radiofrequency ablation is the last treatment option for patients with frequent VT recurrences despite antiarrhythmic drugs. The aim was to present our retrospective catheter ablation data in this group of patients. The majority of 34 patients, who underwent percutaneous endocardial radiofrequency catheter ablation, were male, median age 67.5 years, who presented with electrical storm, had underlying cardiomyopathy after remote inferior wall myocardial infarction and preceding myocardial revascularization procedure, and had been implanted with cardioverter-defibrillator (ICD). Two ablation methods were used: linear ablation and/or scar homogenization. Acute ablation success (non-inducibility of any VT) was achieved in 59 % of procedures. VT could not be interrupted in 2 (6 %) patients. Pericardial tamponade that needed surgical intervention occurred in one procedure (2 %), and was related to inadvertent perforation of the right ventricular apex with a diagnostic catheter. Seven (20 %) patients died and additional 3 were lost from the median of 31 (6–151, rank) months of follow-up. No late VT recurrences were demonstrated in 20 (59 %) patients, and rare in 4 (12 %). Overall, the ablation procedure was successful in 71 % of patients. Catheter ablation gave very good long-term clinical result in about two-thirds of our patients with ischaemic cardiomyopathy and frequent VT recurrences. Catheter ablation, preferably with scar homogenization approach, should be considered early to reduce the number of VT episodes and ICD discharges.
- Open Access
- 24 December 2010
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 13 (6) , 869-875
Electrophysiology of anterograde right-atrial and left-atrial inputs to the atrioventricular node in patients with atrioventricular nodal re-entrant tachycardia
To study anterograde atrioventricular (A-V) nodal electrophysiological properties through the right–atrial (Ri) and left-atrial inputs (Li) under the pharmacological autonomic blockade (AUB) in patients with slow–fast A-V nodal re-entrant tachycardia (AVNRT) and in controls. Twenty-nine patients with slow–fast AVNRT and 15 control subjects were included. Programmed stimulation with single extrastimulus was performed from the right atrial appendage to test the Ri, and from the posterolateral coronary sinus to test the Li. The AUB was induced with intravenous atropine (0.04 mg/kg) and metoprolol (0.15 mg/kg). The A-V nodal conduction times, refractoriness, discontinuous conduction (≥40 ms atrial-His interval ‘jump’), and inducibility of AVNRT or reciprocating beats were compared. The A-V nodal conduction times were longer: (i) through the Ri than Li, (ii) in patients than controls, and (iii) in baseline than after AUB—at slow rates in both groups and at fast rates in patients through the right input only (P < 0.05–0.001). A significantly longer slow pathway effective refractory period was demonstrated through the Li than the Ri in patients in baseline (P < 0.05). The discontinuous conduction was demonstrated 94 times in 25 of 29 (83%) patients and 15 times in 6 of 15 (40%) controls (P < 0.01), and was most frequently encountered with the Ri testing. Likewise, inducibility was manifested most frequently with the Ri testing (P = 0.08), and decreased after AUB during this testing only (P = 0.05). The inherent magnitude of discordance of A-V nodal conduction velocity, refractoriness, and parasympathetic modulation between the Ri and Li to the A-V node may play a role in the aetiology of AVNRT.
- 24 December 2010
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 13 (6) , 869-875
Open AccessElectrophysiology of anterograde right-atrial and left-atrial inputs to the atrioventricular node in patients with atrioventricular nodal re-entrant tachycardia
To study anterograde atrioventricular (A-V) nodal electrophysiological properties through the right–atrial (Ri) and left-atrial inputs (Li) under the pharmacological autonomic blockade (AUB) in patients with slow–fast A-V nodal re-entrant tachycardia (AVNRT) and in controls. Twenty-nine patients with slow–fast AVNRT and 15 control subjects were included. Programmed stimulation with single extrastimulus was performed from the right atrial appendage to test the Ri, and from the posterolateral coronary sinus to test the Li. The AUB was induced with intravenous atropine (0.04 mg/kg) and metoprolol (0.15 mg/kg). The A-V nodal conduction times, refractoriness, discontinuous conduction (≥40 ms atrial-His interval ‘jump’), and inducibility of AVNRT or reciprocating beats were compared. The A-V nodal conduction times were longer: (i) through the Ri than Li, (ii) in patients than controls, and (iii) in baseline than after AUB—at slow rates in both groups and at fast rates in patients through the right input only (P < 0.05–0.001). A significantly longer slow pathway effective refractory period was demonstrated through the Li than the Ri in patients in baseline (P < 0.05). The discontinuous conduction was demonstrated 94 times in 25 of 29 (83%) patients and 15 times in 6 of 15 (40%) controls (P < 0.01), and was most frequently encountered with the Ri testing. Likewise, inducibility was manifested most frequently with the Ri testing (P = 0.08), and decreased after AUB during this testing only (P = 0.05). The inherent magnitude of discordance of A-V nodal conduction velocity, refractoriness, and parasympathetic modulation between the Ri and Li to the A-V node may play a role in the aetiology of AVNRT.
- 1 July 2005
- Published by Elsevier in International Journal of Cardiology
- Vol. 102 (2) , 297-302
Familial biventricular myocardial noncompaction associated with Ebstein's malformation
- 1 July 2005
- Published by Elsevier in International Journal of Cardiology
- Vol. 102 (2) , 297-302
Familial biventricular myocardial noncompaction associated with Ebstein's malformation
- 17 June 2005
- Published by Wiley in Clinical Genetics
- Vol. 68 (2) , 155-160
Familial progressive sinoatrial and atrioventricular conduction disease of adult onset with sudden death, dilated cardiomyopathy, and brachydactyly. A new type of heart‐hand syndrome?
We identified a family with 10 affected members in four generations suffering from adult‐onset progressive sinoatrial and atrioventricular conduction disease, sudden death due to ventricular tachyarrhythmia, dilated cardiomyopathy, and a unique type of brachydactyly with mild hand involvement (short distal, middle, proximal phalanges and clinodactyly) and more severe foot involvement (short distal, proximal phalanges and metatarsal bones, short or absent middle phalanges, terminal symphalangism, duplication of the bases of the second metatarsals, extra ossicles, and syndactyly). The phenotype differences from other reported genetic abnormalities and linkage exclusion of Holt–Oram syndrome, ulnar–mammary syndrome, brachydactyly type B or Robinow syndrome, and cardiac conduction disease or Brugada syndrome loci suggest that we report on a new hereditary heart‐hand syndrome.
- 17 June 2005
- Published by Wiley in Clinical Genetics
- Vol. 68 (2) , 155-160
Familial progressive sinoatrial and atrioventricular conduction disease of adult onset with sudden death, dilated cardiomyopathy, and brachydactyly. A new type of heart‐hand syndrome?
We identified a family with 10 affected members in four generations suffering from adult‐onset progressive sinoatrial and atrioventricular conduction disease, sudden death due to ventricular tachyarrhythmia, dilated cardiomyopathy, and a unique type of brachydactyly with mild hand involvement (short distal, middle, proximal phalanges and clinodactyly) and more severe foot involvement (short distal, proximal phalanges and metatarsal bones, short or absent middle phalanges, terminal symphalangism, duplication of the bases of the second metatarsals, extra ossicles, and syndactyly). The phenotype differences from other reported genetic abnormalities and linkage exclusion of Holt–Oram syndrome, ulnar–mammary syndrome, brachydactyly type B or Robinow syndrome, and cardiac conduction disease or Brugada syndrome loci suggest that we report on a new hereditary heart‐hand syndrome.